2. UroToday Home
  3. Recent Abstracts
  4. Urologic Oncology
  5. Prostate Cancer

ASCO 2013 - Poster: Open-label, multicenter study of sipuleucel-T in men with metastatic castrate resistant prostate cancer (mCRPC) previously treated with sipuleucel-T: Evaluation of antigen presenting cell (APC) activation and ELISPOT data

CHICAGO, IL USA (UroToday.com) - Presented by Beer TM,1 Glode LM,2 Lance RS,3 Greengold RH,4 Sims R,5 Wang Y,5 Sheikh N,5 and Corman JM6 at the American Society of Clinical Oncology (ASCO) Annual Meeting - May 31 - June 4, 2013 - McCormick Place - Chicago, IL USA

asco 2013 beers Open-label multicenter study of sipuleucel-T thumb

1Oregon Health & Science University Knight Cancer Institute, Portland, OR, USA; 2University of Colorado Cancer Center, Aurora, CO, USA; 3Eastern Virginia Medical School, Norfolk, VA, USA; 4South Orange County Medical Research Center, Laguna Hills, CA, USA; 5Dendreon Corporation, Seattle, WA, USA; 6Virginia Mason Medical Center, Seattle, WA, USA


Click HERE to listen to a podcast by Tomasz M. Beer, MD, FACS, one of the participants in this study

The ASCO Annual Meeting brings together more than 25,000 oncology professionals from a broad range of specialties, making it an excellent venue for exploring the theme of the Meeting — "Building Bridges to Conquer Cancer."


asco x

View Full ASCO 2013 Coverage